MedTrace Logo

IRONHEART: Intravenous Iron in Non-ischaemic Heart Failure

NCT06542822 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2024-08-07

No results posted yet for this study

Summary

The aim of this study is to observe the effect of intravenous ferric derisomaltose in participants with non-ischaemic heart failure (LVEF\<40%), iron deficiency (TSATS\<20%) and established on heart failure therapy including Sodium-glucose cotransporter 2 inhibitors (SGLT2i). Participants will undergo baseline laboratory blood tests, cardiac magnetic resonance imaging (cMRI), six-minute walk test, musculoskeletal function test and Kansas City Cardiomyopathy Questionnaire (KCCQ). These investigations will be repeated at 24 hours and 30 days after the administration of intravenous ferric derisomaltose.

Conditions

Interventions

DRUG

Ferric derisomaltose

See group descriptions

Sponsors & Collaborators

  • Portsmouth Hospitals NHS Trust

    collaborator OTHER_GOV

  • University Hospital Southampton NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Andrew S Flett, MBBS BSc MD · University Hospital Southampton NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-15
Primary Completion
2026-02-28
Completion
2027-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06542822 on ClinicalTrials.gov